1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

XFOR
X4 Pharmaceuticals, Inc.US flagNASDAQ Capital Market
2.83
USD
- -
- -
266.92MMarket Cap

Total Valuation

X4 Pharmaceuticals, Inc. carries a market capitalization of 266.92M, placing it among publicly traded companies globally. Its enterprise value stands at 318.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap266.92M
Enterprise Value318.11M

Share Statistics

X4 Pharmaceuticals, Inc. currently has 96.11M shares outstanding.

Shares Outstanding96.11M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 29.07, and the price-to-book ratio stands at 2.89.

PE RatioN/A
PS Ratio29.07
PB Ratio2.89
P/TBV Ratio3.59
P/FCF Ratio-5.85
P/OCF Ratio-5.50

Enterprise Valuation

EV / Sales20.07
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

X4 Pharmaceuticals, Inc. maintains a current ratio of 11.30, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.68, indicating elevated leverage, while an interest coverage ratio of -9.87 demonstrates limited ability to service its debt obligations.

Current Ratio11.30
Quick Ratio10.84
Debt / Equity49.68
Debt / EBITDA-0.90
Interest Coverage-9.87

Financial Efficiency

Return on Equity (ROE)-113.08
Return on Assets (ROA)-50.32
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.68

Taxes

Income Tax-28,000.00
Effective Tax RateN/A

Stock Price Statistics

X4 Pharmaceuticals, Inc.'s stock has declined approximately -18.67816% over the past 52 weeks. The 50-day moving average sits at 3.83, while the 200-day moving average is 3.91.

Beta (5Y)N/A
52-Week Price Change-18.67816%
50-Day Moving Average3.83
200-Day Moving Average3.91
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, X4 Pharmaceuticals, Inc. generated 15.85M in revenue and converted that into -90.14M in net income, yielding earnings per share of -0.91. EBITDA reached -86.24M, while operating income came in at -87.90M.

Revenue15.85M
Gross Profit12.92M
Operating Income-87.90M
Pretax Income-90.17M
Net Income-90.14M
EBITDA-86.24M
EBIT-87.90M
Earnings Per Share (EPS)-0.91

Balance Sheet

X4 Pharmaceuticals, Inc. holds 207.97M in cash and equivalents against 77.22M in total debt, resulting in a net debt position of -118.34M. Total book value stands at 155.45M, with working capital of 199.49M providing operational flexibility.

Cash & Cash Equivalents207.97M
Total Debt77.22M
Net Debt-118.34M
Equity (Book Value)155.45M
Book Value Per Share1.62
Working Capital199.49M

Cash Flow

X4 Pharmaceuticals, Inc. produced -83.74M in operating cash flow over the past twelve months. After subtracting -5.00M in capital expenditures, free cash flow totaled -88.74M - equivalent to -0.90 per share.

Operating Cash Flow-83.74M
Capital Expenditures-5.00M
Free Cash Flow-88.74M
FCF Per Share-0.90

Margins

X4 Pharmaceuticals, Inc. operates with a gross margin of 81.51, reflecting its pricing power and cost economics. The operating margin of -554.71 and net profit margin of -568.80 provide insight into operational efficiency.

Gross Margin81.51
Operating Margin-554.71
Pretax Margin-568.98
Profit Margin-568.80
EBITDA Margin-544.20

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-51.93
FCF Yield-17.09

Stock Splits

X4 Pharmaceuticals, Inc.'s most recent stock split took place on April 28, 2025 with a 30:1 split ratio.

Last Split Date4/28/2025
Split Ratio30:1

Scores

X4 Pharmaceuticals, Inc. posts an Altman Z-Score of -1.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.37